Wells Fargo Maintains Equal-Weight on Carter’s, Lowers Price Target to $80
Wells Fargo analyst Ike Boruchow maintains Carter's (NYSE:CRI) with a Equal-Weight and lowers the price target from $90 to $80.
Why Walmart is Trading Higher By More Than 9%: Here Are 25 Stocks Moving Premarket
Gainers
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) rose 64.4% to $1.43 in pre-market trading. Ayala Pharmaceuticals filed request for withdrawal of registration statement on form S-1.
UBS Maintains Neutral on Carter’s, Lowers Price Target to $72
UBS analyst Jay Sole maintains Carter's (NYSE:CRI) with a Neutral and lowers the price target from $100 to $72.
Thursday Is Your Last Chance To Buy Carter’s Before The Dividend Payout
Thursday marks the last chance for investors to receive the next dividend payout from Carter's (NYSE:CRI).
Expert Ratings for Carter’s
Within the last quarter, Carter's (NYSE:CRI) has observed the following analyst ratings:
Citigroup Downgrades Carter’s to Sell, Lowers Price Target to $68
Citigroup analyst Paul Lejuez downgrades Carter's (NYSE:CRI) from Buy to Sell and lowers the price target from $110 to $68.
Carter’s Earnings Perspective: Return On Invested Capital
According to Benzinga Pro, during Q1, Carter's (NYSE:CRI) earned $67.93 million, a 29.95% increase from the preceding quarter. Carter's's sales decreased to $781.28 million, a 26.43% change since Q4.